Abstract Library

#4128 Validation of a 3-gene signature of response to axitinib in patients with advanced NETs

Introduction: Axitinib in combination with SSA significantly improved ORR and PFS per central blinded radiological assessment, as compared to placebo and SSA in 253 EP-NETs in the AXINET trial. The magnitude of the benefit, however, was limited. We recently described a 3-gene tumor transcriptomic signature predictive of response to axitinib in NET patients.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Carretero-Puche C, Antón-Pascual B, Capdevila J, Benavent M,

Keywords: axitinib, sunitinib, tyrosine kinase inhibitor, predictive biomarker, signature, elisa,

#4086 Prognostic significance of metabolomics clusters in extra-pancreatic NETs: Lung NET sub-analysis

Introduction: Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the aberrant changes that support cancer cells proliferation and survival. In a previous metabolomics study carried out by our group, multiplatform untargeted metabolomic profiling (GC-MS, CE-MS and LC-MS) performed on plasma samples from 77 advanced G1-2 extra-pancreatic NET patients demonstrated that these patients have a distinct metabolomic profile, and identified methionine, porphyrin and tryptophan metabolism as the most relevant dysregulated pathways associated with the prognosis of NETs. Furthermore, a 3-metabolite signature was able to stratify patients in 3 distinct prognostic clusters, with cluster 3 associated with the best prognosis.

Conference:

Presenting Author:

Authors: La Salvia A, Lens-Pardo A, Carretero-Puche C, Capdevila J, Benavent M,

Keywords: metabolimics, prognostic biomarker, lung neuroendocrine tumor, metabolomic signature,

#3275 MicroRNA prognostic signature in neuroendocrine neoplasias (NENs) of lung and GEP origin: In silico analysis of target genes and pathways

Introduction: Molecular knowledge of NENs has increased in the last years. Nevertheless, the lack of in vivo models makes it difficult to guide functional experiments to better understand the biological implications of described molecular alterations. In this context, and as miRNAs contribute to regulate gene expression, we performed an in silico analysis to explore target genes and involved pathways regulated by an 8-miRNA prognostic signature that we recently developed in NENs, that stratified patients in 3 prognostic groups (Espinosa-Olarte P et al, ESMO 2020).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Espinosa Olarte P, Soldevilla B, Carretero-Puche C, Molina-Pinelo S, Robles C,

Keywords: neuroendocrine neoplasia, miRNAs, genes, pathways, prognosis,

#3271 Comprehensive metabolomic plasma profiling identifies novel potential diagnostic biomarkers in patients with advanced neuroendocrine tumors

Introduction: NETs are heterogeneous neoplasms that have the capacity to secrete hormones or bioactive molecules. Dysregulated metabolism is one of the key hallmarks of cancer and the altered expression of metabolic enzymes is deeply involved in tumor development, progression, and metastasis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Soldevilla B, Lens-Pardo A, López-López �, Carretero-Puche C, La Salvia A,

Keywords: NETs, metabolic signalling, plasma metabolites, diagnostic biomarker,